Cover Image

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical P. aeruginosa isolates collected in the Middle East - SMART 2016-2018

Saved in:

Bibliographic Details
Main Authors:	I Alekseeva (Author), S Lob (Author), M Hackel (Author), K Young (Author), M Motyl (Author), D Sahm (Author)
Format:	Book
Published:	Elsevier, 2020-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Activity of Ceftolozane/tazobactam and Imipenem/relebactam against Clinical Enterobacteriaceae Isolates Collected in the Middle East - SMART 2016-2018
by: I Alekseeva, et al.
Published: (2020)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
by: Marco Fiore, et al.
Published: (2021)

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
by: Jesus Ruiz, et al.
Published: (2020)

Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition
by: Jan Thomas De Pourcq, et al.
Published: (2024)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
by: Marta Palombo, et al.
Published: (2023)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>
by: Worapong Nasomsong, et al.
Published: (2022)

Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data
by: Silvia Garazzino, et al.
Published: (2020)

In Vitro Activity of Aztreonam-avibactam and Ceftazidime-avibactam against Pseudomonas aeruginosa Collected in a Global Surveillance Program in the Africa/Middle East, 2014-2017
by: I Morrissey, et al.
Published: (2020)

Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections
by: Pratik Bhagunde, et al.
Published: (2019)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
by: Soo Min Jang, et al.
Published: (2021)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
by: Z. S. Khankhel, et al.
Published: (2022)

Cost-effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
by: Jaesh Naik, et al.
Published: (2023)

The Effectiveness of Imipenem-Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
by: Krisztina M. Papp-Wallace, et al.
Published: (2023)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
by: Mario Pezzi, et al.
Published: (2019)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
by: Goodlet KJ, et al.
Published: (2016)

Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report
by: Yuta Ibe, et al.
Published: (2023)

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> Infections
by: Aisling R. Caffrey, et al.
Published: (2022)

Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis
by: Reza Abniki, MS, et al.
Published: (2024)

Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study
by: Hakeam A. Hakeam, et al.
Published: (2022)

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
by: Skalweit MJ
Published: (2015)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
by: Giancola SE, et al.
Published: (2016)

Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in the Outpatient Setting
by: Francesco Venuti, et al.
Published: (2023)

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against <i>Pseudomonas aeruginosa</i> Infection-Isolates from an Academic Medical Center in Thailand
by: Woraphot Tantisiriwat, et al.
Published: (2022)

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against <i>KPC</i>-Producing <i>K. pneumoniae</i> Collected from Bacteremic Patients, 2018 to 2020
by: Federica Bovo, et al.
Published: (2022)

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
by: Munjal Patel, et al.
Published: (2022)

Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i>
by: Anthony Sophonsri, et al.
Published: (2024)

Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
by: Fabián Hernández
Published: (2020)

Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury
by: Laura Butragueño-Laiseca, et al.
Published: (2020)

Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
by: Xing Tan, et al.
Published: (2019)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
by: María José Contreras-Gómez, et al.
Published: (2022)

Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Enterobacterales</i> from Five Latin American Countries
by: Juan Carlos García-Betancur, et al.
Published: (2022)

The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis
by: Li-Ting Wang, et al.
Published: (2021)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
by: Rémy A. Bonnin, et al.
Published: (2023)

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
by: Paolo Gaibani, et al.
Published: (2022)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>
by: Arhodoula Papadomanolaki, et al.
Published: (2022)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020)

In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals
by: Nezar M. Bahabri, et al.
Published: (2022)

Role of Relebactam in the Antibiotic Resistance Acquisition in <i>Pseudomonas aeruginosa</i>: In Vitro Study
by: Maria Paz Ventero, et al.
Published: (2023)

Clinical Outcomes of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy
by: Wasim S. El Nekidy, et al.
Published: (2024)